Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BacTech Environmental (BAC) partners with Sharechest in hopes of attaining new investors
  • The company removes and transforms harmful contaminants like arsenic into benign EPA-approved products for landfill
  • BacTech continues to investigate the prospects of establishing additional modern bioleaching facilities across North and South America
  • Sharechest has been built to provide an innovative web application solution that streamlines the discovery process for companies seeking investors
  • BacTech Environmental Corporation (BAC) is down 8.33 per cent, trading at C$0.06 at 12:53 pm EST

Sharechest partners with BacTech Environmental Corporation (BAC) to streamline communications with potential investors.

BacTech is a proven environmental technology company delivering solutions commercially to process and recover preferred metals.

It works by removing and transforming harmful contaminants like arsenic into benign EPA-approved products for landfill.

Using its bioleaching method, the company can tap into numerous environmental and economic advantages.

BacTech is planning to build a new owner-operated bioleaching facility in Tenguel, Ecuador, and continues to investigate the prospects of establishing additional modern bioleaching facilities across North and South America.

Sharechest has been built to provide an innovative web application solution that streamlines the discovery process for companies seeking investors.

It seamlessly integrates into the company’s existing website and is a magnet for investors interested in learning or investing in the company. 

BacTech uses naturally occurring bacteria, harmless to humans and the environment, to neutralize toxic mining sites with high-pay potential.

BacTech Environmental Corporation (BAC) is down 8.33 per cent, trading at C$0.06 at 12:53 pm EST.


More From The Market Herald
Neuralink - Founder, Elon Musk.

" Neuralink brain chips approved for human trials

Elon Musk’s Neuralink, a brain implant firm, has received regulatory approval for U.S. human trials.

" Marvell stock spikes 30 per cent on Q1 news  

Marvell Technology (NASDAQ:MRVL) shares rose more than 30 per cent Friday.

" Ontario lithium project suite advancing on schedule and on budget

Beyond Lithium’s (CSE:BY) 2023 Phase 1 exploration program in Ontario is progressing on schedule and on budget.